This work illustrates how integrated population PK modeling of antibody-conjugated payload and free payload analytes for an ADC can inform development strategies for targeted therapies—particularly in complex oncology settings.
This work illustrates how integrated population PK modeling of antibody-conjugated payload and free payload analytes for an ADC can inform development strategies for targeted therapies—particularly in complex oncology settings.